ClinicalTrials.gg
Active, not recruitingNCT05669625Updated Jun 18, 2023

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

A Phase 3 interventional study of Investigational live attenuated varicella vaccine and Placebo of live attenuated varicella vaccine in Varicella, sponsored by China National Biotec Group Company Limited. Active, not recruiting at 13 sites in China. Open to participants aged 1 Year to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by China National Biotec Group Company Limited (part of Sinopharm) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,440
Allocation
Randomized
Ages
1 Year to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
4th of 36
12,440 · median 404
Started
2022
with 2 others
Phase 3
12 of 36
2 open now
Registered
30th of 36
by date
Lead sponsor
1 of 36
China National Biotec Group Company Limited

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 4th largest by enrollment, is one of 3 that started in 2022, is one of 12 in phase 3, and was the 30th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

Read the detailed description

This trial is aim to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children aged 1-12 years old.

This study will be conducted in two stage. the stage 1 adopts an open design, and 20 subjects aged 18\~59 and 13\~17 years old (18\~59 years old→ 13\~17 years old, sequentially enrolled) are enrolled, and 1 dose of the trial vaccine is administered to explore safety.

The stage 2 adopts a randomized, blinded, placebo-controlled design, 12400 healthy participants aged 1-12 years old will be randomly assigned into experimental group or control group with the ratio 1:1.

03

Conditions studied

  • Varicella

Browse trials for

Keywords

  • vaccine efficacy
  • varicella vaccine
  • safety
  • immunogenicity
04

Who can participate

Ages eligible
1 Year to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer between 13 - 59 years old for Stage 1, 1-12 years old for Stage 2, and be able to provide legal identification ;
  • Subject and/or guardian has the ability to understand study requirements and processes, consent to participate in clinical trials, and sign forms;
  • Consent to use effective during study participation, no pregnancy and no family planning (for women of or their spouses);
  • Axillary temperature ≤ 37.0 °C on the day of enrollment;

Exclusion criteria

Exclusion Criteria:

  • Has received any varicella vaccine before ( Not applicable to Stage 1);
  • Has history of varicella or herpes zoster infection, or contact with varicella/shingles patients or suspected varicella/shingles patients within 30 days before enrollment ( Not applicable to Stage 1);
  • Currently using salicylates (including salicylic acid, aspirin, diflunisalin, p-aminosalicylate (sodium), dicalicylate, benoxate, etc.), or plan to use it for a long time during the study;
  • Have had febrile illness (axillary temperature ≥ 38.5 °C) or used antipyretic, analgesic, anti-allergic drugs (such as acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination;
  • Have a history of allergy to vaccine components and or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, local allergic necrosis (Arthus) reaction, severe urticaria, etc;
  • Have a history of epilepsy, convulsions or convulsions, and have a family history of severe neurological disease or psychosis
  • or diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other diseases;
  • With severe congenital malformations, hereditary diseases, serious cardiovascular diseases, serious liver/kidney diseases, complicated diabetes, malignant tumors, and severe malnutrition
  • Immunosuppressant therapy, such as long-term oral or injectable therapy (≥ 14 days, dose ≥2 mg/kg/day or ≥20 mg/day or equivalent to prednisone), within 3 months prior to enrollment or planned within 30 days of vaccination, but topical medications (e.g., ointments, eye drops, inhalers, or nasal sprays) are not restricted
  • Have received blood/blood-related products or immunoglobulins 3 months prior to vaccination, or plan to use such products 30 days after vaccination;
  • Have received a within 30 days prior to the trial vaccine, or any vaccine within 14 days prior to vaccination;
  • Asplenectomy or splenectomy due to any condition (e.g. splenectomy);
  • Those with a history of thrombocytopenia or other coagulation disorders, which may cause to subcutaneous injection;
  • Suffering from various infectious, purulent or allergic skin diseases;
  • Are participating in other or unregistered clinical trials of products (drugs, vaccines or devices, etc.), or have plans to participate in other clinical trials before the end of this clinical trial;
  • Has any other factors that are not suitable for participation in the clinical trial in the judgment of the investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12,440 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Single subcutaneous injection of the investigational vaccine (0.5 ml)

    Biological: Investigational live attenuated varicella vaccine

  • Placebo comparator
    Placebo Group

    Single subcutaneous injection of the investigational placebo (0.5 ml)

    Biological: Placebo of live attenuated varicella vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. The incidences of varicella in each group

    The first 24 cases of varicella occurred 30 days after injection will be collected

    Time frame: number of cases reported 30 days after vaccination

  2. The efficacy of the live attenuated varicella vaccine

    The vaccine efficacy will be calculated based on the reported cases occurred 30 days after vaccination

    Time frame: number of cases reported 30 days after vaccination

Secondary outcomes

  1. The vaccine efficacy against laboratory-confirmed cases of moderate and severe varicella

    The vaccine efficacy will be calculated based on the reported cases occurred 30 days after vaccination

    Time frame: number of cases reported 30 days after vaccination

  2. The vaccine efficacy against clinical-confirmed cases

    calculated based on the reported cases occurred 30 days after vaccination

    Time frame: number of cases reported 30 days after vaccination

  3. The incidences of adverse events (AEs)

    AEs occurred within 30 days after injection will be collected

    Time frame: within 30 days after vaccination

  4. The incidences of serious adverse events (SAEs)

    SAEs occurred within 6 months after vaccination will be collected

    Time frame: at least 6 months after vaccination

  5. The geometric mean titer (GMT) in the immunogenicity subgroup

    Geometric mean titer (GMT) will be measured before and 30 days after vaccination

    Time frame: 30 days after vaccination

  6. The seroconversion rate of the immunogenicity subgroup

    The seroconversion rate will be calculated before and 30 days after vaccination

    Time frame: 30 days after vaccination

  7. The geometric mean fold increase (GMI) of the immunogenicity subgroup

    Geometric mean fold increase (GMI) of the immunogenicity group will be calculated based on the geometric mean titer

    Time frame: 30 days after vaccination

  8. The immune persistence of the immunogenicity subgroup

    Geometric mean titer (GMT) will be measured

    Time frame: 1 year, 2 years, and 3 years after vaccination

07

Study locations

13 sites
  • Sinan County Center for Disease Control and Prevention
    Tongren, Guizhou, China
  • Songtao Miao Autonomous County Center for Disease Control and Prevention
    Tongren, Guizhou, China
  • Yuping Dong Autonomous County Center for Disease Control and Prevention
    Tongren, Guizhou, China
  • Qi County Center for Disease Control and Prevention
    Hebi, Henan, China
  • Wuzhi County Center for Disease Control and Prevention
    Jiaozuo, Henan, China
  • Wuyang County Center for Disease Control and Prevention
    Luohe, Henan, China
  • Pei County Center for Disease Control and Prevention
    Xuzhou, Jiangsu 221600, China
  • Huaiyin District Center for Disease Control and Prevention
    Xuzhou, Jiangsu 223300, China
  • Mianyang Anzhou District Center for Disease Control and Prevention
    Mianyang, Sichuan, China
  • Southern County Center for Disease Control and Prevention
    Nanchong, Sichuan, China
  • Neijiang City Center for Disease Control and Prevention
    Neijiang, Sichuan, China
  • Lancang Lahu Autonomous County Center for Disease Control and Prevention
    Pu'er, Yunnan, China
  • Yanshan County Center for Disease Control and Prevention
    Wenshan, Yunnan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Apr 2024, 15 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's planned 15 months is above that.

Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 3, 2023
StartActual
Dec 26, 2022
Primary completionEst.
Apr 14, 2024
CompletionEst.
Sep 14, 2026
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669625
Collaborators
Beijing Institute of Biological Products Co Ltd., Jiangsu Province Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Dec 26, 2022
Primary completion
Apr 14, 2024 (estimated)
Completion
Sep 14, 2026 (estimated)
Last update
Jun 18, 2023

Study contacts

Hongxing Pan
principal investigator · Jiangsu Province Centers for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion